AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT06592482
- Locations
- 🇺🇸
Research Site, Saint Paul, Minnesota, United States
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
Not Applicable
Recruiting
- Conditions
- Cough-Variant Asthma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06590740
- Locations
- 🇨🇳
Research Site, Zunyi, China
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
Phase 2
Active, not recruiting
- Conditions
- Obesity or Overweight
- Interventions
- Drug: Placebo comparator
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 262
- Registration Number
- NCT06595238
- Locations
- 🇬🇧
Research Site, Rotherham, United Kingdom
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
Phase 1
Recruiting
- Conditions
- Advanced Solid TumoursNon-Small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 430
- Registration Number
- NCT06599502
- Locations
- 🇬🇧
Research Site, Newcastle-Upon-Tyne, United Kingdom
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 310
- Registration Number
- NCT06579092
- Locations
- 🇬🇧
Research Site, Witney, United Kingdom
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Phase 2
Recruiting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 384
- Registration Number
- NCT06579105
- Locations
- 🇬🇧
Research Site, Yate, United Kingdom
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06576765
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
Not yet recruiting
- Conditions
- Bleeding
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 168
- Registration Number
- NCT06575517
Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia
Recruiting
- Conditions
- Severe Asthma
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT06566885
- Locations
- 🇷🇺
Research Site, Tomsk, Russian Federation
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Phase 1
Recruiting
- Conditions
- Large B-cell LymphomaB-cell Non-Hodgkin LymphomaMantle-cell LymphomaChronic Lymphocytic LeukaemiaSmall Lymphocytic Leukaemia
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT06564038
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath